BONE AND BONES;
CHEMILUMINESCENT MEASUREMENTS;
HUMANS;
IMMUNORADIOMETRIC ASSAY;
KIDNEY FAILURE, CHRONIC;
OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE);
PARATHYROID HORMONE;
PRACTICE GUIDELINES;
RENAL DIALYSIS;
UNITED STATES;
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy
Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus M, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446-456, 2003
Confirmation of the upward shift in the commonly used Nichols Advantage intact PTH assay compared to the publication based Nichols IRMA intact PTH assay
Cantor T, Demers L: Confirmation of the upward shift in the commonly used Nichols Advantage intact PTH assay compared to the publication based Nichols IRMA intact PTH assay. J Am Soc Nephrol 15:771A, 2004
Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Renal Data System: USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004
The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992-2002
Foley RN, Li S, Lui J, Gilbertson DT, Chen S-C, Collins AJ: The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992-2002. J Am Soc Nephrol 16:210-218, 2005
Comparison between the Nichols and Scantibodies IRMA PTH assays of 1999 and 2003 for stored samples
Cantor T, Glowacki P, D'Amour P: Comparison between the Nichols and Scantibodies IRMA PTH assays of 1999 and 2003 for stored samples. J Am Soc Nephrol 14:901A, 2003
